National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare"

Nigel S. B. Rawson ^1,2,3 *

Cited by CrossRef:

1- Tang S, Gong Y, Liu M, Yang D, Tang K. Do Drug Accessibility and OOP Burden Affect Health-Related Quality of Life of Patients With Chronic Diseases? — EQ-5D-5L Evaluation Evidence From Five Districts in China. Front Public Health. 2021;9 [Crossref]

2- Wen X, Xu L, Chen X, Wu R, Luo J, Wan Y, Mao Z. A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China. Front Pharmacol. 2023;14 [Crossref]

3- Wen X, Wang Z, Xu L, Luo J, Geng X, Chen X, Yang Y, Cui D, Mao Z. The impacts of the “4+7” pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study. Front Pharmacol. 2022;13 [Crossref]

4- Wen X, Yin S, Cui L, Mao L, Lin Z, Yaermaimaiti Z, Geng X, Li Y, Yang Y, Cui D, Mao Z. The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis. Front Public Health. 2021;9 [Crossref]

5- Dutescu I, Hillier S. Encouraging the Development of New Antibiotics: Are Financial Incentives the Right Way Forward? A Systematic Review and Case Study. IDR. 2021;Volume 14:415 [Crossref]

6- MacKinnon L, Kerman N, Socías M, Brar R, Bardwell G. Primary care embedded within permanent supportive housing for people who use substances: A qualitative study examining healthcare access in Vancouver, Canada. Health Social Care Comm. 2022;30(6) [Crossref]

Submit Your Paper Archive